



Correction to: Darinaparsin: First Approval

James E. Frampton¹

Published online: 14 November 2022
© Springer Nature Switzerland AG 2022

Correction to: Drugs
<https://doi.org/10.1007/s40265-022-01795-z>

Abstract, second sentence, which currently reads:

An intravenous formulation of darinaparsin has been approved for the treatment of relapsed or refractory PTCL in Japan and is currently in clinical development for this indication in China, the USA and the EU.

Should read:

An intravenous formulation of darinaparsin has been approved for the treatment of relapsed or refractory PTCL in Japan, and preparation for the next stage of the clinical development program for this indication is currently underway in China, the USA and the EU.

Introduction, fourth paragraph, first sentence, which currently reads:

Intravenous darinaparsin is currently in clinical development for relapsed or refractory PTCL in China, the USA and the EU [8].

Should read:

Preparation for the next stage of the clinical development program of intravenous darinaparsin in relapsed or refractory PTCL is currently underway in China, the USA and the EU [8].

The original article can be found online at <https://doi.org/10.1007/s40265-022-01795-z>.

✉ James E. Frampton
dru@adis.com

¹ Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand